F. TUĞLULAR T Et Al. , "Post Authorization Safety of Lenalidomide Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma in Turkey," Clinical Lymphoma Myeloma & Leukemia , vol.15, pp.301-302, 2015
TUĞLULAR T, F. Et Al. 2015. Post Authorization Safety of Lenalidomide Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma in Turkey. Clinical Lymphoma Myeloma & Leukemia , vol.15 , 301-302.
TUĞLULAR T, F., PEHLİVAN, M., SARI, H. İ., AYYILDIZ, M. O., SAYDAM, G., SÖNMEZ, M., ... BEŞIŞIK S, K.(2015). Post Authorization Safety of Lenalidomide Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma in Turkey. Clinical Lymphoma Myeloma & Leukemia , vol.15, 301-302.
TUĞLULAR T, FIRATLI Et Al. "Post Authorization Safety of Lenalidomide Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma in Turkey," Clinical Lymphoma Myeloma & Leukemia , vol.15, 301-302, 2015
TUĞLULAR T, FIRATLI T. Et Al. "Post Authorization Safety of Lenalidomide Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma in Turkey." Clinical Lymphoma Myeloma & Leukemia , vol.15, pp.301-302, 2015
TUĞLULAR T, F. Et Al. (2015) . "Post Authorization Safety of Lenalidomide Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma in Turkey." Clinical Lymphoma Myeloma & Leukemia , vol.15, pp.301-302.
@article{article, author={FIRATLI TUĞLULAR T Et Al. }, title={Post Authorization Safety of Lenalidomide Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma in Turkey}, journal={Clinical Lymphoma Myeloma & Leukemia}, year=2015, pages={301-302} }